공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

결핵 : 파이프라인 리뷰

Tuberculosis (Infectious Disease) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 232861
페이지 정보 영문 428 Pages
가격
US $ 2,500 ₩ 2,959,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,919,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,878,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


결핵 : 파이프라인 리뷰 Tuberculosis (Infectious Disease) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 428 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

결핵은 림프절 및 혈관을 통해 전신의 기관으로 확산될 가능성이 있는 세균 감염증입니다. 폐에서 발견되는 경우가 많고 자각 증상이 없는 경우(잠복성 결핵)부터 활동기에 이르기까지의 기간이 있으며, 전신적인 권태감, 기침, 혈액이 섞인 점액 배출, 피로감, 호흡 곤란, 체중 감소, 흉통 등의 증상이 있습니다.

결핵(Tuberculosis) 치료제 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

서론

결핵 개요

치료제 개발

치료제 평가

치료제 개발 참여 기업

약제 개요

휴지 상태의 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

부록

도표

LSH 17.07.24

List of Tables

List of Tables

  • Number of Products under Development for Tuberculosis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Companies, 2021 (Contd..1)
  • Number of Products under Development by Companies, 2021 (Contd..2)
  • Number of Products under Development by Companies, 2021 (Contd..3)
  • Number of Products under Development by Companies, 2021 (Contd..4)
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products under Development by Universities/Institutes, 2021 (Contd..1)
  • Number of Products under Development by Universities/Institutes, 2021 (Contd..2)
  • Number of Products under Development by Universities/Institutes, 2021 (Contd..3)
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Companies, 2021 (Contd..2)
  • Products under Development by Companies, 2021 (Contd..3)
  • Products under Development by Companies, 2021 (Contd..4)
  • Products under Development by Companies, 2021 (Contd..5)
  • Products under Development by Companies, 2021 (Contd..6)
  • Products under Development by Companies, 2021 (Contd..7)
  • Products under Development by Universities/Institutes, 2021
  • Products under Development by Universities/Institutes, 2021 (Contd..1)
  • Products under Development by Universities/Institutes, 2021 (Contd..2)
  • Products under Development by Universities/Institutes, 2021 (Contd..3)
  • Products under Development by Universities/Institutes, 2021 (Contd..4)
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Target, 2021 (Contd..1)
  • Number of Products by Stage and Target, 2021 (Contd..2)
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)
  • Number of Products by Stage and Mechanism of Action, 2021 (Contd..2)
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Tuberculosis - Pipeline by Abera Bioscience AB, 2021
  • Tuberculosis - Pipeline by Akshaya Bio Inc, 2021
  • Tuberculosis - Pipeline by AN2 Therapeutics Inc, 2021
  • Tuberculosis - Pipeline by Archivel Farma SL, 2021
  • Tuberculosis - Pipeline by Astellas Pharma Inc, 2021
  • Tuberculosis - Pipeline by AstraZeneca Plc, 2021
  • Tuberculosis - Pipeline by Astria Therapeutics Inc, 2021
  • Tuberculosis - Pipeline by Austrianni GmbH, 2021
  • Tuberculosis - Pipeline by BioLingus AG, 2021
  • Tuberculosis - Pipeline by BioNTech SE, 2021
  • Tuberculosis - Pipeline by Bioversys AG, 2021
  • Tuberculosis - Pipeline by Bristol-Myers Squibb Co, 2021
  • Tuberculosis - Pipeline by C&O Pharmaceutical Technology (Holdings) Ltd, 2021
  • Tuberculosis - Pipeline by CanSino Biologics Inc, 2021
  • Tuberculosis - Pipeline by Changzhou Yinsheng Pharmaceutical Co Ltd, 2021
  • Tuberculosis - Pipeline by Chengdu Keen Biotechnology Co Ltd, 2021
  • Tuberculosis - Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2021
  • Tuberculosis - Pipeline by Collaborations Pharmaceuticals Inc, 2021
  • Tuberculosis - Pipeline by Consegna Pharma Inc, 2021
  • Tuberculosis - Pipeline by Crestone Inc, 2021
  • Tuberculosis - Pipeline by Daiichi Sankyo Co Ltd, 2021
  • Tuberculosis - Pipeline by Demuris Ltd, 2021
  • Tuberculosis - Pipeline by Eisai Co Ltd, 2021
  • Tuberculosis - Pipeline by Eli Lilly and Co, 2021
  • Tuberculosis - Pipeline by Ena Therapeutics Pty Ltd, 2021
  • Tuberculosis - Pipeline by Enyo Pharma SA, 2021
  • Tuberculosis - Pipeline by EpiVax Inc, 2021
  • Tuberculosis - Pipeline by Evotec SE, 2021
  • Tuberculosis - Pipeline by Exscientia Ltd, 2021
  • Tuberculosis - Pipeline by EyeGene Inc, 2021
  • Tuberculosis - Pipeline by Faron Pharmaceuticals Oy, 2021
  • Tuberculosis - Pipeline by Fimbrion Therapeutics Inc, 2021
  • Tuberculosis - Pipeline by Gamaleya Federal Research Center of Epidemiology and Microbiology, 2021
  • Tuberculosis - Pipeline by GC Pharma, 2021
  • Tuberculosis - Pipeline by GlaxoSmithKline Plc, 2021
  • Tuberculosis - Pipeline by Globeimmune Inc, 2021
  • Tuberculosis - Pipeline by Greffex Inc, 2021
  • Tuberculosis - Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, 2021
  • Tuberculosis - Pipeline by Guangzhou Egg Biotechnology Co Ltd, 2021
  • Tuberculosis - Pipeline by HanaVax Inc, 2021
  • Tuberculosis - Pipeline by Hsiri Therapeutics LLC, 2021
  • Tuberculosis - Pipeline by Immodulon Therapeutics Ltd, 2021
  • Tuberculosis - Pipeline by Immunitor Inc, 2021
  • Tuberculosis - Pipeline by ImmunoBiology Ltd, 2021
  • Tuberculosis - Pipeline by Innovare R & D SA De CV, 2021
  • Tuberculosis - Pipeline by Kolmar Pharma Co Ltd, 2021
  • Tuberculosis - Pipeline by L2 Diagnostics LLC, 2021
  • Tuberculosis - Pipeline by Lead Discovery Center GmbH, 2021
  • Tuberculosis - Pipeline by LegoChem Biosciences Inc, 2021
  • Tuberculosis - Pipeline by MannKind Corp, 2021
  • Tuberculosis - Pipeline by Matinas BioPharma Holdings Inc, 2021
  • Tuberculosis - Pipeline by Medicines Development Ltd, 2021
  • Tuberculosis - Pipeline by Merck & Co Inc, 2021
  • Tuberculosis - Pipeline by MetalloPharm LLC, 2021
  • Tuberculosis - Pipeline by Microbiotix Inc, 2021
  • Tuberculosis - Pipeline by Mountain Valley MD Holdings Inc, 2021
  • Tuberculosis - Pipeline by Mycosynthetix Inc, 2021
  • Tuberculosis - Pipeline by Nearmedic Plus Ltd, 2021
  • Tuberculosis - Pipeline by NovoBiotic Pharmaceuticals LLC, 2021
  • Tuberculosis - Pipeline by NTxBio LLC, 2021
  • Tuberculosis - Pipeline by Opal Biosciences Ltd, 2021
  • Tuberculosis - Pipeline by Otsuka Pharmaceutical Co Ltd, 2021
  • Tuberculosis - Pipeline by Pai Life Sciences Inc, 2021
  • Tuberculosis - Pipeline by Palisades Therapeutics, 2021
  • Tuberculosis - Pipeline by Pathens Inc, 2021
  • Tuberculosis - Pipeline by PDS Biotechnology Corp, 2021
  • Tuberculosis - Pipeline by PeptiDream Inc, 2021
  • Tuberculosis - Pipeline by Pfizer Inc, 2021
  • Tuberculosis - Pipeline by Pharmapraxis, 2021
  • Tuberculosis - Pipeline by Quratis Inc, 2021
  • Tuberculosis - Pipeline by QureTech Bio AB, 2021
  • Tuberculosis - Pipeline by Qurient Co Ltd, 2021
  • Tuberculosis - Pipeline by Sanofi, 2021
  • Tuberculosis - Pipeline by Sequella Inc, 2021
  • Tuberculosis - Pipeline by Serum Institute of India Pvt Ltd, 2021
  • Tuberculosis - Pipeline by Shanghai H&G Biotech, 2021
  • Tuberculosis - Pipeline by Shanghai Jiatan Pharmaceutical Technology Co Ltd, 2021
  • Tuberculosis - Pipeline by Spero Therapeutics Inc, 2021
  • Tuberculosis - Pipeline by Sphaera Pharma Pte Ltd, 2021
  • Tuberculosis - Pipeline by Target Medicals LLC, 2021
  • Tuberculosis - Pipeline by TB-Stopper, 2021
  • Tuberculosis - Pipeline by Tibet Rhodiola Pharmaceutical Holding Co Ltd, 2021
  • Tuberculosis - Pipeline by TVAX Biomedical Inc, 2021
  • Tuberculosis - Pipeline by Tydock Pharma Srl, 2021
  • Tuberculosis - Pipeline by Uvax Bio LLC, 2021
  • Tuberculosis - Pipeline by Vaccibody AS, 2021
  • Tuberculosis - Pipeline by Vaxil Bio Therapeutics Ltd, 2021
  • Tuberculosis - Pipeline by Vaxinano SE, 2021
  • Tuberculosis - Pipeline by Vaxine Pty Ltd, 2021
  • Tuberculosis - Pipeline by Vaxxit Srl, 2021
  • Tuberculosis - Pipeline by Vichem Chemie Research Ltd, 2021
  • Tuberculosis - Pipeline by Vir Biotechnology Inc, 2021
  • Tuberculosis - Pipeline by Zata Pharmaceuticals Inc, 2021
  • Tuberculosis - Dormant Projects, 2021
  • Tuberculosis - Dormant Projects, 2021 (Contd..1)
  • Tuberculosis - Dormant Projects, 2021 (Contd..2)
  • Tuberculosis - Dormant Projects, 2021 (Contd..3)
  • Tuberculosis - Dormant Projects, 2021 (Contd..4)
  • Tuberculosis - Dormant Projects, 2021 (Contd..5)
  • Tuberculosis - Dormant Projects, 2021 (Contd..6)
  • Tuberculosis - Dormant Projects, 2021 (Contd..7)
  • Tuberculosis - Dormant Projects, 2021 (Contd..8)
  • Tuberculosis - Dormant Projects, 2021 (Contd..9)
  • Tuberculosis - Dormant Projects, 2021 (Contd..10)
  • Tuberculosis - Dormant Projects, 2021 (Contd..11)
  • Tuberculosis - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Tuberculosis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tuberculosis - Drugs In Development, 2021, provides an overview of the Tuberculosis (Infectious Disease) pipeline landscape.Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tuberculosis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Tuberculosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Tuberculosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tuberculosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 14, 10, 1, 61, 38 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 6, 9, 37 and 33 molecules, respectively.

Tuberculosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tuberculosis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Tuberculosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tuberculosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tuberculosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tuberculosis (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tuberculosis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tuberculosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Tuberculosis - Overview
  • Tuberculosis - Therapeutics Development
  • Tuberculosis - Therapeutics Assessment
  • Tuberculosis - Companies Involved in Therapeutics Development
  • Tuberculosis - Drug Profiles
  • Tuberculosis - Dormant Projects
  • Tuberculosis - Discontinued Products
  • Tuberculosis - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q